These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12920198)

  • 41. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK; Keyghobadi M; Moore C; Meshul CK
    Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
    Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
    Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL; Puttfarcken PS; Kuntzweiler TA; Briggs CA; Anderson DJ; Campbell JE; Piattoni-Kaplan M; McKenna DG; Wasicak JT; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
    Zhang D; McGregor M; Decker MW; Quik M
    J Pharmacol Exp Ther; 2014 Oct; 351(1):25-32. PubMed ID: 25034405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple roles for nicotine in Parkinson's disease.
    Quik M; Huang LZ; Parameswaran N; Bordia T; Campos C; Perez XA
    Biochem Pharmacol; 2009 Oct; 78(7):677-85. PubMed ID: 19433069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
    Zhang D; Bordia T; McGregor M; McIntosh JM; Decker MW; Quik M
    Mov Disord; 2014 Apr; 29(4):508-17. PubMed ID: 24515328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
    Quik M; McIntosh JM
    J Pharmacol Exp Ther; 2006 Feb; 316(2):481-9. PubMed ID: 16210393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
    Borah A; Mohanakumar KP
    Neurochem Int; 2010 Jan; 56(2):357-62. PubMed ID: 19931335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
    Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
    J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.
    Perez XA; Bordia T; McIntosh JM; Grady SR; Quik M
    Mol Pharmacol; 2008 Sep; 74(3):844-53. PubMed ID: 18583454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.
    Fernagut PO; Li Q; Dovero S; Chan P; Wu T; Ravenscroft P; Hill M; Chen Z; Bezard E
    PLoS One; 2010 Nov; 5(11):e14053. PubMed ID: 21124922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior.
    Inden M; Takata K; Yanagisawa D; Ashihara E; Tooyama I; Shimohama S; Kitamura Y
    Neurochem Int; 2016 Mar; 94():74-81. PubMed ID: 26911419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum.
    O'Leary KT; Parameswaran N; Johnston LC; McIntosh JM; Di Monte DA; Quik M
    J Pharmacol Exp Ther; 2008 Oct; 327(1):124-9. PubMed ID: 18606871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Possible involvement of neuronal nicotinic acetylcholine receptors in compensatory brain mechanisms at early stages of Parkinson's disease].
    Kryukova EV; Shelukhina IV; Kolacheva AA; Alieva AK; Shadrina MI; Slominsky PA; Kasheverov IE; Utkin YN; Ugrumov MV; Tsetlin VI
    Biomed Khim; 2017 May; 63(3):241-247. PubMed ID: 28781257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.